Always Evolving for a Better World
For over a century, we’ve been an unstoppable force, from developing medicines that save and improve lives to vaccines that protect them. Today, with the combined expertise of CSL Behring, CSL Plasma, CSL Seqirus, and CSL Vifor—and our singular commitment to relentlessly innovate—CSL’s offerings are more diverse than ever to help ensure patients and people everywhere get the treatments they deserve. We’re always improving so life can, too.
CSL Behring's portfolio of innovative medicines includes a wide range of recombinant and plasma-derived products for treating bleeding disorders, immune deficiencies and chronic inflammatory demyelinating polyneuropathy, as well as hereditary angioedema and Alpha 1 Antitrypsin Deficiency.
CSL Plasma operates one of the world’s largest and most sophisticated plasma collection networks, with more than 300 plasma collection centers in U.S., Europe and China. Plasma collected at CSL Plasma facilities are used by CSL Behring for the purpose of manufacturing and delivering its life-saving therapies to people in more than 100 countries.
Seqirus opened as a company in 2015, from the joining of bioCSL, our former influenza division and the Novartis Influenza Vaccines business. Together the two elevated Seqirus to the second largest influenza company in the world.
CSL Vifor is a strong and rapidly growing presence in nephrology, and is committed to launching the next generation of therapies to truly address the full spectrum of kidney disease, with a focus on dialysis and rare disease. This is supported by our founding heritage and expertise in iron deficiency therapy, helping to support a broad range of patients in need.